HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ming-Lung Yu Selected Research

Antiviral Agents (Antivirals)

9/2022Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes.
9/2022Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021.
4/2022Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients.
1/2022Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
1/2022Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR).
1/2022Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations.
1/2022Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
1/2022Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine.
1/2022Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.
1/2022Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ming-Lung Yu Research Topics

Disease

129Chronic Hepatitis C
09/2022 - 01/2002
111Infections
08/2022 - 01/2002
62Fibrosis (Cirrhosis)
07/2022 - 03/2002
60Hepatocellular Carcinoma (Hepatoma)
04/2022 - 04/2005
37Chronic Hepatitis B
02/2022 - 02/2006
28Hepatitis C
01/2022 - 02/2006
26Liver Cirrhosis (Hepatic Cirrhosis)
10/2021 - 03/2002
22Hepatitis B
07/2022 - 02/2009
22Neoplasms (Cancer)
02/2022 - 02/2006
16Viremia
01/2022 - 01/2002
13Non-alcoholic Fatty Liver Disease
10/2022 - 09/2008
10Liver Diseases (Liver Disease)
10/2022 - 01/2007
10Hepatitis
07/2022 - 06/2007
10Insulin Resistance
11/2017 - 04/2009
8Coinfection
10/2021 - 10/2004
7Chronic Renal Insufficiency
02/2022 - 03/2019
7Virus Diseases (Viral Diseases)
02/2022 - 07/2003
7Fatty Liver
12/2021 - 12/2007
6Body Weight (Weight, Body)
07/2022 - 02/2006
6HIV Infections (HIV Infection)
07/2020 - 01/2014
5Hypertension (High Blood Pressure)
01/2022 - 12/2007
5Type 2 Diabetes Mellitus (MODY)
01/2022 - 02/2008
4Diabetes Mellitus
01/2022 - 09/2012
4Disease Progression
01/2022 - 06/2017
4Obesity
07/2012 - 12/2007
3Inflammation (Inflammations)
10/2021 - 03/2008
3Chronic Kidney Failure (Chronic Renal Failure)
08/2021 - 01/2014
3Liver Neoplasms (Liver Cancer)
12/2016 - 07/2013
3Metabolic Syndrome (Dysmetabolic Syndrome X)
09/2012 - 04/2010
3Cholelithiasis
11/2011 - 04/2010
3Persistent Infection
10/2011 - 02/2009
3End Stage Liver Disease
03/2009 - 12/2006
2Fatigue
10/2022 - 02/2019
2COVID-19
09/2022 - 01/2020
2Glucose Intolerance
09/2022 - 12/2007
2Hyperlipidemias (Hyperlipidemia)
01/2022 - 01/2021
2Sexually Transmitted Diseases (Sexually Transmitted Disease)
01/2022 - 01/2022

Drug/Important Bio-Agent (IBA)

77Antiviral Agents (Antivirals)IBA
09/2022 - 08/2009
61Ribavirin (Virazole)FDA LinkGeneric
01/2022 - 10/2004
54InterferonsIBA
01/2022 - 07/2003
39RNA (Ribonucleic Acid)IBA
01/2022 - 01/2002
25Hepatitis B Surface Antigens (HBsAg)FDA Link
12/2021 - 09/2003
19DNA (Deoxyribonucleic Acid)IBA
12/2021 - 01/2002
19Interferon-alpha (Interferon Alfa)IBA
04/2021 - 01/2002
16Alanine Transaminase (SGPT)IBA
12/2021 - 01/2002
12Glucose (Dextrose)FDA LinkGeneric
09/2022 - 12/2007
12Proteins (Proteins, Gene)FDA Link
03/2022 - 05/2011
11Hepatitis B e AntigensIBA
07/2022 - 01/2007
11Biomarkers (Surrogate Marker)IBA
04/2022 - 11/2007
10Triglycerides (Triacylglycerol)IBA
01/2021 - 07/2006
7nasIBA
01/2022 - 07/2012
7Uric Acid (Urate)IBA
03/2020 - 09/2008
7Fetal Proteins (Fetoprotein)IBA
01/2020 - 04/2013
6Pharmaceutical PreparationsIBA
02/2022 - 01/2014
6SofosbuvirIBA
02/2022 - 03/2016
6CytokinesIBA
01/2022 - 03/2008
6alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2022 - 02/2015
6asunaprevirIBA
01/2021 - 12/2017
6daclatasvirIBA
01/2021 - 12/2017
6Lamivudine (Epivir)FDA Link
11/2016 - 12/2006
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2014 - 06/2003
5Aspartate Aminotransferases (Aspartate Transaminase)IBA
09/2022 - 01/2011
5Carrier Proteins (Binding Protein)IBA
03/2022 - 08/2017
5Sorafenib (BAY 43-9006)FDA Link
02/2022 - 10/2019
5Transaminases (Aminotransferases)IBA
01/2022 - 06/2003
5Insulin (Novolin)FDA Link
10/2021 - 01/2010
5peginterferon alfa-2a (Pegasys)FDA Link
12/2020 - 02/2009
5LipidsIBA
11/2020 - 07/2008
5micaIBA
01/2019 - 12/2015
5CholesterolIBA
03/2016 - 07/2008
4Tenofovir (Viread)FDA Link
07/2022 - 01/2020
4entecavirFDA Link
02/2022 - 11/2016
4AntigensIBA
01/2022 - 11/2016
4NucleotidesIBA
01/2022 - 11/2020
4BilirubinIBA
01/2022 - 10/2019
4NucleosidesIBA
01/2022 - 11/2020
4Phospholipases (Phospholipase)IBA
03/2016 - 03/2015
3wisteria lectinIBA
03/2022 - 08/2017
3velpatasvirIBA
02/2022 - 12/2018
3Pioglitazone (Actos)FDA Link
10/2021 - 09/2008
3AlbuminsIBA
04/2021 - 01/2020
3Long Noncoding RNAIBA
01/2021 - 01/2019
3glecaprevir and pibrentasvirIBA
01/2021 - 12/2018
3Indicators and Reagents (Reagents)IBA
01/2021 - 03/2002
3dasabuvirIBA
12/2018 - 11/2016
3ombitasvirIBA
12/2018 - 11/2016
3paritaprevirIBA
12/2018 - 11/2016
3Ritonavir (Norvir)FDA Link
12/2018 - 11/2016
3InterleukinsIBA
03/2018 - 01/2013
3Serum AlbuminIBA
01/2015 - 11/2007
3Surface Antigens (Surface Antigen)IBA
04/2014 - 06/2007
2Ferritins (Ferritin)IBA
09/2022 - 02/2019
2sofosbuvir drug combination ledipasvirIBA
08/2022 - 12/2018
2EnzymesIBA
02/2022 - 04/2010

Therapy/Procedure

106Therapeutics
10/2022 - 01/2002
9Renal Dialysis (Hemodialysis)
10/2021 - 02/2002
9Liver Transplantation
01/2021 - 01/2007
4Drug Therapy (Chemotherapy)
02/2022 - 02/2006
3Aftercare (After-Treatment)
03/2020 - 02/2009
3Blood Transfusion (Blood Transfusions)
03/2019 - 01/2002